Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy.
Fu Y, Wang A, Zhou J, Feng W, Shi M, Xu X, Zhao H, Cai L, Feng J, Lv X, Zhang X, Xu W, Zhang Z, Ma G, Wang J, Zhou T, Zhao D, Fang H, Liu Z, Huang JA.
Fu Y, et al. Among authors: zhou j, zhou t.
Front Oncol. 2023 Jun 27;13:1236311. doi: 10.3389/fonc.2023.1236311. eCollection 2023.
Front Oncol. 2023.
PMID: 37441428
Free PMC article.